Compugen Licenses Gencarta to Avalon in Drug Target Collaboration

Apr 03, 2001

NEW YORK, April 3 – Compugen has licensed its new Gencarta database of annotated genomic, transcription, and proteomic data to Avalon Pharmaceuticals of Gaithersburg, MD, and has agreed to collaborate with Avalon on drug and diagnostic target identification research, the companies said Tuesday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Testing Less Likely

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three for Immunotherapy

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

This Week in Genome Research

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Cancer-Fighting Zombies

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.

Main menu